Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.1% – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price was down 8.1% during mid-day trading on Friday . The stock traded as low as $23.18 and last traded at $23.43. Approximately 54,709 shares were traded during trading, a decline of 73% from the average daily volume of 202,782 shares. The stock had previously closed at $25.49.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on DNTH shares. Wedbush reduced their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Raymond James raised their price objective on Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Oppenheimer raised their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday. Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Stock Down 8.8 %

The business has a 50-day moving average price of $27.65 and a 200-day moving average price of $26.63. The firm has a market capitalization of $687.90 million, a P/E ratio of -9.41 and a beta of 1.84.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The firm had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Dianthus Therapeutics by 250.0% during the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after acquiring an additional 384,182 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Dianthus Therapeutics by 860.5% in the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock valued at $2,095,000 after buying an additional 72,509 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Dianthus Therapeutics by 104.0% in the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock valued at $242,000 after buying an additional 4,506 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. raised its holdings in shares of Dianthus Therapeutics by 281.9% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company’s stock valued at $1,022,000 after buying an additional 29,159 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of Dianthus Therapeutics by 38.6% in the second quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock valued at $788,000 after buying an additional 8,473 shares during the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.